Related Experiment Video
Updated: Dec 30, 2025
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
An approach to heart failure and diabetes mellitus
1Division of Cardiology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA. gfonarow@mednet.ucla.edu
Insights
Patients with diabetes and heart failure often have poor outcomes due to underutilization of key medications. Standard therapy with ACE inhibitors, aldosterone antagonists, and beta-blockers is crucial for improving survival and reducing hospitalizations.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Diabetes mellitus is a chronic, progressive condition leading to significant microvascular and macrovascular complications.
- Diabetes is a major independent risk factor for heart failure, with a substantial overlap in patient populations.
- Neurohormonal activation is a key pathophysiological mechanism in insulin resistance, diabetes, cardiovascular events, and heart failure progression.
Purpose of the Study:
- To highlight the critical role of neurohormonal activation in diabetes and heart failure.
- To emphasize the underutilization of guideline-recommended pharmacologic interventions for patients with both conditions.
- To advocate for the standard use of specific drug classes in managing comorbid diabetes and heart failure.
Main Methods:
- Review of existing literature and clinical guidelines on diabetes and heart failure management.
- Analysis of the pathophysiological roles of neurohormonal systems in these diseases.
- Discussion of pharmacologic interventions targeting these systems, including ACE inhibitors, aldosterone antagonists, and beta-blockers.
Main Results:
- Pharmacologic interventions targeting neurohormonal systems (ACE inhibition, aldosterone antagonism, beta-blockade) reduce morbidity and mortality in diabetes and heart failure.
- Despite proven benefits, these medications are significantly underutilized.
- Guidelines recommend ACE inhibitors and beta-blockers for heart failure patients, with aldosterone antagonists for severe and increasingly mild-to-moderate cases.
Conclusions:
- Beta-blockade, alongside ACE inhibition and aldosterone antagonism, should be standard therapy for all patients with comorbid diabetes and heart failure.
- Physicians' concerns regarding potential side effects of beta-blockers in diabetic patients may contribute to underprescription.
- Ensuring eligible patients receive these evidence-based, life-prolonging therapies is essential for improving outcomes.
Abstract:
Diabetes mellitus is a chronic progressive disease that results in microvascular and macrovascular complications. Diabetes is a significant independent risk factor for heart failure, and there are a substantial number of patients with diabetes and heart failure. Neurohormonal activation plays an important pathophysiologic role in insulin resistance, diabetes, cardiovascular events, and progression of heart failure. Pharmacologic intervention in these neurohormonal systems (ie, angiotensin-converting enzyme [ACE] inhibition, aldosterone antagonism, and beta-adrenergic blockade) has been shown to decrease the morbidity and mortality of diabetes and of heart failure. Despite this knowledge, ACE inhibitors, aldosterone antagonists, and beta-blockers are grossly underutilized, and deaths and hospitalizations due to heart failure have steadily increased. Guidelines for the management of heart failure recommend the use of ACE inhibitors and beta-blockers in patients with mild, moderate, and severe heart failure with or without diabetes. Aldosterone antagonists are recommended in severe heart failure and recent data also support their use in mild to moderate heart failure. Concerns about increased incidence of hypoglycemia, worsening dyslipidemia, and decreased insulin sensitivity with beta-blockers may be preventing physicians from prescribing these agents for their patients with diabetes who have heart failure. Beta-blockade, in conjunction with ACE inhibition and aldosterone antagonism, should be standard therapy for all patients with diabetes and heart failure. Furthermore, every effort should be made to ensure that eligible patients are treated with these evidence-based, guideline-recommended, life-prolonging therapies.
